Discovery of a First-in-Class Reversible DNMT1-Selective Inhibitor with Improved Tolerability and Efficacy in Acute Myeloid Leukemia

Due to improved in vivo tolerability compared with decitabine, GSK3685032 yielded superior tumor regression and survival mouse models of acute myeloid leukemia.